Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version

SECTIONS

Changes to This Summary (05/26/2016)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Tumor Biology of Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT)

Revised text to state that additional genomic alterations in other genes are very uncommon in patients with SMARCB1-associated AT/RT, and there are no other genes that are recurrently mutated. Added that despite the absence of recurring genomic alterations beyond SMARCB1, biologically distinctive subsets of AT/RT have been identified (cited Torchia et al. and Johann et al. as references 14 and 15, respectively). Also added text about three biologically distinctive subsets of atypical teratoid/rhabdoid tumor that were identified using DNA methylation arrays for 150 AT/RT tumors and gene expression arrays for 67 AT/RT tumors.

This summary is written and maintained by the PDQ Pediatric Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® - NCI's Comprehensive Cancer Database pages.

< Previous section
Current Clinical Trials

Next section >
About This PDQ Summary